5-Aminolevulinic acid / LDH Cancer Research Results

5-ALA, 5-Aminolevulinic acid: Click to Expand ⟱
Features:
Aminolevulinic acid (5-ALA) is primarily known for its role as a biosynthetic precursor to heme

5-ALA — 5-aminolevulinic acid (5-aminolevulinic acid; often administered as the hydrochloride salt) is an endogenous, small-molecule heme biosynthesis precursor used clinically as a pro-photosensitizer for tumor visualization and, when paired with an appropriate light source, photodynamic therapy (PDT). It is formally a drug/prodrug modality whose functional identity is to drive intracellular accumulation of the fluorescent porphyrin protoporphyrin IX (PpIX), enabling fluorescence-guided resection (notably high-grade glioma) and light-activated cytotoxicity in appropriately illuminated tissues. Standard abbreviations include 5-ALA, ALA; the key active photochemical mediator is PpIX. Tumor selectivity is primarily metabolic (differential porphyrin/heme pathway handling), rather than target-receptor binding, and clinical performance is strongly constrained by light penetration and local oxygen availability.

Primary mechanisms (ranked):

  1. Heme biosynthesis precursor loading causing preferential intracellular PpIX accumulation and fluorescence in many tumor/preneoplastic tissues
  2. Light-activated PpIX photochemistry generating ROS (notably singlet oxygen) and acute oxidative injury
  3. Mitochondrial damage and cell-death execution (apoptosis/necrosis; can include MPTP involvement) after photostress
  4. Local vascular injury and microenvironment collapse (perfusion impairment; oxygen- and geometry-dependent)
  5. Inflammatory / immunogenic cell-death signaling and downstream immune modulation (context-dependent)

Bioavailability / PK relevance: Route-locked. Oral ALA-HCl is used for intraoperative fluorescence in glioma with timed dosing prior to anesthesia/surgery; topical formulations are used for dermatologic PDT with local incubation followed by office-based illumination. Systemic exposure is clinically relevant for oral use (and photosensitivity risk), while topical use is primarily local with workflow defined by incubation + illumination.

In-vitro vs systemic exposure relevance: Many “dark” in-vitro ALA studies use concentrations that are not directly exposure-matched to clinical plasma levels; the clinically dominant cytotoxic mechanism is typically light-triggered, PpIX-mediated photochemistry rather than concentration-only pharmacology.

Clinical evidence status: Established clinical deployment as an adjunct optical imaging agent for fluorescence-guided resection of suspected high-grade glioma (approved) and as a photosensitizer precursor for dermatologic PDT (approved for actinic keratosis; additional indications vary by jurisdiction). Oncology PDT applications beyond these settings are heterogeneous and commonly investigational or center-specific.

-ALA is used in medical therapies such as photodynamic therapy (PDT) for certain types of cancer and skin conditions.
- Inside the cells, ALA enters the heme biosynthetic pathway and is converted to protoporphyrin IX (PpIX), a potent photosensitizer.
-The light activates the accumulated PpIX, leading to the production of reactive oxygen species (ROS).
-FDA approved June 2017 as a photo-imaging tool during neurosurgery for malignant glioma. The patient takes an oral dose of Gleolan 3 hours before surgery.

Mechanistic pathway ranking for 5-ALA (oncology focus)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Heme biosynthesis loading to PpIX accumulation ↑ PpIX (often higher and more spatially heterogeneous) ↑ PpIX (typically lower; tissue-dependent) R Fluorescence contrast prerequisite for PDD/FGS and PDT substrate formation Tumor selectivity is largely metabolic (porphyrin pathway flux, transporter expression, ferrochelatase activity, iron availability); not a receptor-targeted drug in the classic sense.
2 ROS photogeneration by excited PpIX ↑ ROS (requires light + O₂) ↑ ROS (requires light + O₂) P Type II (singlet oxygen) and Type I oxidative damage driving phototoxicity This is the dominant “killing” lever for PDT; absent illumination, ROS burst is not the main mode.
3 Mitochondria / MPTP ↓ mitochondrial function; ↑ MPTP (context-dependent) ↓ mitochondrial function; ↑ MPTP (context-dependent) P Energetic collapse and amplification of cell-death signaling PpIX can localize to mitochondria in many settings; mitochondrial photodamage is a common execution node for PDT.
4 Cell-death programs ↑ apoptosis/necrosis (dose-dependent) ↑ apoptosis/necrosis (dose-dependent) R Tumor cell kill and lesion clearance Phenotype depends on light dose-rate, oxygenation, subcellular PpIX localization, and baseline stress defenses.
5 Vascular injury and perfusion failure ↓ perfusion (context-dependent) ↓ perfusion (context-dependent) R Secondary tumor control via microvascular damage Most relevant in vivo; magnitude depends on illumination geometry and local vascular photosensitization.
6 NRF2 antioxidant stress response ↑ NRF2 programs (context-dependent) ↑ NRF2 programs (context-dependent) G Adaptive resistance to oxidative photostress Often a downstream consequence of photodynamic redox stress; clinically relevant as a resistance axis in repeat/low-dose contexts.
7 Iron handling and ferrochelatase constraint ↓ ferrochelatase constraint can yield ↑ PpIX (model-dependent) Variable R Controls PpIX-to-heme conversion and thus fluorescence/phototoxic substrate levels Iron availability and heme-pathway enzyme balance can shift PpIX accumulation; a key reason for inter-tumor variability.
8 Chemosensitization or Radiosensitization ↑ sensitivity (context-dependent) Variable R Combination leverage via oxidative injury and stress overload Evidence is indication- and protocol-specific; synergy is plausible but not universal and can be limited by light/oxygen constraints.
9 Clinical Translation Constraint Depth-limited light delivery; oxygen dependence; heterogeneous PpIX; workflow timing; photosensitivity risk; tissue-selective illumination required — Defines where 5-ALA is clinically practical For most solid tumors, light penetration and geometry (and local O₂) are the hard constraints; these often dominate over “molecular pathway” considerations.


LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
3452- 5-ALA,    5-ALA Is a Potent Lactate Dehydrogenase Inhibitor but Not a Substrate: Implications for Cell Glycolysis and New Avenues in 5-ALA-Mediated Anticancer Action
- in-vitro, GBM, T98G - in-vitro, GBM, LN-18 - in-vitro, GBM, U87MG
Glycolysis↓, LDH↓, eff↝, ECAR↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

ECAR↓, 1,   Glycolysis↓, 1,   LDH↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↝, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:332  Target#:906  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page